MolDX's New Transplant Rejection LCD Takes Effect August 30: What Labs Need to Know

ScreenMyGene Team·Published August 29, 2026·8 min read·Clinically reviewed by Dr. Ashraf, Ph.D.
Clinical laboratory scientist reviewing blood collection tubes at a molecular diagnostics bench under navy and teal lighting

Short answer: On August 30, 2026, MolDX's revised solid organ allograft rejection LCD takes effect in all five MolDX jurisdictions. It allows six kidney, twelve heart, and twelve lung surveillance timepoints in year one and four per year in years two and three, permits only one molecular test per encounter, and requires separate Z-Code identifiers for surveillance versus for-cause testing.

What takes effect on August 30, 2026

MolDX finalized its rewritten policy on molecular testing for solid organ allograft rejection on July 16, 2026, and the notice period closes August 29. For services performed on or after August 30, 2026, the new LCD governs Medicare coverage of donor-derived cell-free DNA (dd-cfDNA), gene expression profiling (GEP), and proteomic assays used to assess transplanted kidneys, hearts, and lungs.

The policy carries a different LCD number in each MolDX jurisdiction but identical coverage language: L40058 (Palmetto GBA, J-J and J-M), L40060 and L40062 (Noridian), L40140 (CGS Administrators), and L40249 (WPS). Every one of them carries an original effective date of 08/30/2026. The companion billing and coding articles — A60146, A60152, A60155, A60161, and A60274 — share that date.

Labs that treat this as a routine LCD refresh will misread it. The coverage envelope got wider, but the claim-level rules got tighter and more specific, and several of them are enforced by automated edits rather than by post-payment review.

The surveillance cadence is now written into policy

The most consequential change is that MolDX put explicit surveillance timepoint numbers into the coverage criteria. Under the final LCD, protocol (surveillance) testing in an asymptomatic patient "may include the following number of timepoints in the first year post-transplantation: Kidney (6), Heart (12), and Lung (12)." After year one, surveillance may continue "at a frequency of 4 per year in years 2 and 3 post-transplantation."

Allowed surveillance timepoints per patient MolDX solid organ allograft rejection LCD, effective 08/30/2026 0 4 8 12 6 4 Kidney 12 4 Heart 12 4 Lung Year 1 post-transplant Years 2 and 3 (per year) Source: CMS Medicare Coverage Database, LCD L40140 / L40058, Coverage Indications, effective 08/30/2026.
MolDX wrote per-organ surveillance timepoint allowances directly into the coverage criteria rather than leaving cadence to clinical judgment.

These numbers are more generous than the draft. As health policy analyst Bruce Quinn documented in his review of the final policy, MolDX raised first-year kidney surveillance from four tests to six and doubled the years two and three allowance from two per year to four. CareDx, whose AlloSure and AlloMap assays sit at the center of this policy, saw its shares jump more than 20% on the announcement.

Kidney surveillance: draft LCD vs. final LCD Allowed timepoints per patient after comment period Year 1 4 → 6 +50% allowed volume Years 2–3 2 → 4 +100% per year, per patient Response-to-comments document for the final policy runs 194 pages — a measure of how much revenue rides on each cadence number. Source: Quinn B. “Assessing the New MolDx LCD for Transplant Rejection,” Discoveries in Health Policy, July 16, 2026.
Commenters won a materially larger surveillance envelope, but not open-ended utilization.

Surveillance versus for-cause is now a billing distinction, not just a clinical one

The LCD defines two mutually exclusive testing contexts. For-cause testing is the evaluation of a patient with clinical suspicion of rejection — documented physical or biological signs of organ injury. Surveillance (protocol) testing is evaluation of an asymptomatic patient for subclinical acute rejection.

The billing article turns that distinction into a hard requirement: "Different Z-Code identifiers must be used for protocol vs. for-cause testing." A lab that has been billing a single DEX Z-Code for both intents needs to register and map a second identifier before August 30, or its claim data will misrepresent the intended use MolDX is trying to track.

Two related timing rules follow from the same distinction. Surveillance testing "will not be reimbursed if for-cause testing has been performed within the prior month." And a patient being actively evaluated for rejection — tested for clinical suspicion within the prior month — is not eligible for surveillance testing at all.

The LCD does not, however, define how large or how persistent a creatinine rise must be to convert a patient from surveillance to for-cause. That gap is a post-payment exposure: a nephrologist may reasonably document concern, and a reviewer may later disagree that the documentation met the threshold. Labs should assume the medical record, not the requisition checkbox, will be the evidence.

The automated denial edits labs should model before go-live

Claim conditions that trigger denial MolDX billing and coding article A60146, effective 08/30/2026 More than one molecular allograft test per encounter Any additional service billed after the first will be denied. Molecular test on the same date of service as biopsy Automated denial; appealable for manual review in rare qualifying cases. Surveillance within one month of for-cause testing Not reimbursed; patient is considered actively under evaluation. Surveillance beyond 5 years post-transplant No test has met policy criteria to date; denied but appealable. dd-cfDNA-only test before 2 weeks post-transplant Unless the specific assay carries a different stated minimum interval. Source: CMS Medicare Coverage Database, Billing and Coding Article A60146, Article Text, effective 08/30/2026.
Several of these are automated edits. Modeling them against historical claims volume is the fastest way to size the revenue impact before go-live.

Each claim must carry one unit of service, the appropriate DEX Z-Code identifier placed adjacent to the CPT code in the narrative field, and a supporting ICD-10-CM code. For Part B, that placement is Loop 2400 or SV101-7 on the 837P, or Box 19 on a paper claim. For Part A, it is line SV202-7 on the 837I, or Block 80 on the UB-04. MolDX specifically warns against adding any extra characters on the SV101-7 line.

Diagnosis coding is narrower than most transplant programs assume

The billing article names thirteen ICD-10-CM codes that support medical necessity: T86.10, T86.19, T86.20, T86.298, T86.810, T86.818, T86.819, Z48.21, Z48.22, Z48.24, Z94.0, Z94.1, and Z94.2. That list covers kidney, heart, and lung complication codes, aftercare encounters, and transplant status.

It also names five codes that explicitly do not support medical necessity: the entire N17 acute kidney failure family (N17.0, N17.1, N17.2, N17.8, N17.9). A kidney transplant recipient presenting with rising creatinine is a plausible candidate for a for-cause dd-cfDNA test, and acute kidney failure is a plausible clinical impression — but coding the claim that way will not get it paid. If your requisition workflow lets ordering clinicians free-text a diagnosis that maps to N17, that is a denial pipeline. Our guide to why genetic testing claims get denied covers the broader pattern, and our ICD-10 coding reference for genetic testing walks through diagnosis selection.

Which assays are already on the list

The billing article publishes a table of tests that have completed a MolDX Technical Assessment and are deemed policy-compliant for specific indications. It includes AlloMap, AlloSure, and HeartCare (CareDx); Prospera (Natera); Tutivia (Verici Dx); TruGraf (Eurofins Transplant Genomics); Viracor TRAC (Eurofins); and GraftAssureCore (Insight Molecular Diagnostics). Indications are assay-specific — AlloSure Lung, for example, is listed for surveillance in bilateral lung transplants only, and AlloMap requires testing at least 55 days post-transplant.

Tests not on that list are not automatically excluded, but they need to clear a Technical Assessment demonstrating analytical validity, clinical validity in the intended population, and equivalence or superiority to already-covered comparators. The LCD also states that multianalyte and combination tests "must demonstrate superiority and additive benefit when compared to respective single analytes or components" — a meaningful bar for anyone marketing a paired dd-cfDNA plus GEP strategy.

What this means for lab operations and RCM

Three concrete tasks before August 30. First, confirm your DEX Z-Code registrations include distinct identifiers for surveillance and for-cause intents, and that your LIS can select between them based on order data rather than manual entry. Second, build a per-patient, per-organ timepoint counter that knows the post-transplant date, because the frequency limits are cumulative across the year and across ordering sites. Third, audit your diagnosis code mapping for N17 codes and any transplant diagnosis outside the thirteen-code supporting list.

The strategic read is consistent with how MolDX has been operating across its portfolio. It is receptive to biopsy-sparing technology and willing to broaden coverage when evidence is tied to a specific analyte, organ, population, and intended use — and it is unwilling to defer to physician preference or general enthusiasm. Labs that document to that standard get paid. For related context, see our overview of MolDX's expanding national footprint and our primer on Medicare coverage for genetic testing.

Frequently asked questions

Does this LCD apply outside MolDX jurisdictions?

No. It binds the MolDX-participating MACs — Palmetto GBA, Noridian, CGS, and WPS — under LCD numbers L40058, L40060, L40062, L40140, and L40249. Non-MolDX MACs and commercial payers set their own policies, though commercial plans frequently mirror MolDX criteria for molecular diagnostics.

Can a lab bill both a dd-cfDNA test and a gene expression test on the same encounter?

Not as two separate services. The LCD permits only one molecular allograft test per patient encounter; additional services billed after the first are denied. A single combination assay may include more than one analyte, but it must demonstrate superiority and additive benefit over its individual components.

What happens if a molecular test and a biopsy occur on the same day?

An automated denial is issued for the molecular test. The LCD permits simultaneous testing only in very high-risk patients with overt signs of rejection where the molecular result is complementary to the biopsy, and MolDX states it expects these situations to be extremely rare. The denial can be appealed for manual review.

Is surveillance testing covered beyond three years post-transplant?

Potentially, but only where peer-reviewed evidence or society guidelines support the cadence for that analyte and organ in later years. As of this policy, MolDX states no test has met criteria for surveillance past five years post-transplantation; those claims will be denied, with appeal available for manual review.

What is the single most common avoidable denial under this policy?

Diagnosis coding. The N17 acute kidney failure codes are explicitly listed as not supporting medical necessity, yet they are a natural clinical impression for a transplant recipient with rising creatinine. Mapping orders to the thirteen supporting codes — the T86, Z48, and Z94 families — removes a large, entirely preventable denial category.

This article is educational information for laboratory, revenue cycle, and clinical professionals. It is not medical advice, legal advice, coding advice, or a guarantee of payment. Coverage policies, code sets, and effective dates change; always verify against the current CMS Medicare Coverage Database and your MAC's published guidance before submitting claims or making clinical decisions. ScreenMyGene does not determine coverage for any individual claim. Learn more about our work at ScreenMyGene.

Sources: CMS Medicare Coverage Database, LCD L40140 — MolDX: Molecular Testing for Solid Organ Allograft Rejection (CGS Administrators, effective 08/30/2026); CMS Medicare Coverage Database, Billing and Coding Article A60146 (Palmetto GBA, effective 08/30/2026); CMS Medicare Coverage Database LCD search results for L40058, L40060, L40062, and L40249; Quinn B., “Assessing the New MolDx LCD for Transplant Rejection,” Discoveries in Health Policy, July 16, 2026; CareDx Inc., “CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination,” July 16, 2026.